A new study just published in International Urology and Nephrology (Pazir et al) demonstrates that HIVEC with mitomycin C has a similar oncological efficacy and safety profile to standard BCG therapy in high-risk, non-muscle-invasive bladder cancer (NMIBC).
The data of patients with high-risk papillary NMIBC treated with adjuvant intravesical BCG instillations or HIVEC between June 2017 and August 2022 were analysed retrospectively.
48 patients (24 in the BCG group and 24 in the HIVEC group) were included in the study.
24 patients who received HIVEC were matched 1:1 with patients receiving BCG therapy based on tumour characteristics (tumour stage grade), age, gender, smoking status and the number of tumours (single or multiple).
HIVEC and standard BCG treatments were compared in terms of recurrence-free survival (RFS), progression-free survival (PFS), and adverse events.
The median follow-up times of the BCG and HIVEC groups were 32 and 28 months respectively (p = 0.11).
The results showed there was no significant difference between the groups in terms of
1. The 24-month RFS (BCG 83% vs HIVEC 88%, p = 0.64)
2. The 24-month PFS (BCG 100% vs HIVEC 94%, p = 0.61).